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cell carcinoma
G Sonpavde
1 and TK Choueiri*,2
1Urologic Medical Oncology, University of Alabama at Birmingham (UAB) Comprehensive Cancer Center, Birmingham, AL 35294, USA;
2Kidney Cancer
Center, Dana-Farber Cancer Institute, Harvard Medical School, 450 Brookline Ave., Boston, MA 02215, USA
Despite recent advances, metastatic renal cell carcinoma remains largely an incurable disease. Vascular endothelial growth factor and
mammalian target of rapamycin inhibitors have provided improvements in clinical outcomes. High-dose interleukin 2 remains an
option for highly selected patients and is associated with durable remissions in a small minority of patients. The toxicity profiles of
specific agents and patient characteristics and comorbidities and costs have an important role in the current choice of therapy. Major
challenges encountered in developing molecular biomarkers to guide therapy are tumour heterogeneity and standardisation of tissue
collection and analysis. Although biomarkers are in their infancy of development, they should be a priority in early preclinical and
clinical development in order to guide rational tailored development of emerging agents.
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Systemic therapy for clear cell (CC)-renal cell carcinoma (RCC) has
been dramatically altered with the addition of vascular endothelial
growth factor (VEGF) and mammalian target of rapamycin (mTOR)
inhibitors to the therapeutic armamentarium (Table 1) However,
most patients are not cured and the median progression-free
survival (PFS) is 8–12 months in the first-line setting and 4–5
months following VEGF inhibitors. In the absence of biomarkers
predictive for activity, patients are currently selected based on
eligibility criteria in pivotal phase III trials, patient preferences,
toxicity profiles, comorbidities and costs.
Given the modest increments provided by VEGF and mTOR
inhibitors coupled with their toxicities and comorbidities pre-
valent in RCC patients, optimal patient selection is necessary to
maximise outcomes. There is a need to incorporate molecular
factors in clinical decision making to optimise the therapeutic
index and facilitate more rational therapy. This review focuses on
biomarkers to guide the therapy of metastatic CC-RCC.
CANDIDATE MOLECULAR BIOMARKERS BASED ON
TUMOUR BIOLOGY
A knowledge of molecular biology and mechanisms of resistance is
necessary to provide insights to develop predictive biomarkers
(Figure 1) (Bergers and Hanahan, 2008). Tumour tissue ampli-
fications of relevant genes or proteins in the pathways targeted by
the agent or the alternative pathways that mediate resistance may
be hypothesised to guide therapy. In addition, host genomics may
modulate drug metabolism and mediate activity, toxicities
and outcomes. Somatic mutations or loss of the tumour
suppressor, Von Hippel Lindau (VHL) by the epigenetic pathways,
frequently occurs in CC-RCC. Loss of VHL function upregulates
hypoxia-inducible factor (HIF), a transcription factor that leads to
the amplification of VEGF, in addition to a number of other growth
factors (Kaelin, 2008). Indeed, alternative pro-angiogenic pathways
(interleukin-8, fibroblast growth factor, ephrin and the angiopoietin–
Tie pathways) may drive tumorigenesis. The mTOR pro-survival
pathway lies downstream of the PI3K/Akt pathway and is regulated
by the PTEN tumour-suppressor gene. The mTOR phosphorylation
induces translation of messenger RNAs encoding cell-cycle regula-
tors and transcription factors that promote proliferation, including
HIF. The mTOR inhibition can be expected to directly inhibit
tumour cell proliferation, as well as inhibit growth factors regulated
by HIF, including VEGF production. The mTORC1 inhibition has
been reported to upregulate the PI3K/AKT pathway, which may
engender compensatory mTORC2 signalling. The alternative path-
ways that enhance epithelial mesenchymal transition, invasion,
metastasis (for example, hepatocyte growth factor-MET, insulin-like
growth factor and Wnt), metabolic pathways, proliferation (ERK/
M A P Ka n dc - m y c )a n di m m u n o s u p p r e s s i o n( f o re x a m p l e ,b y
myeloid derived suppressor cells) may also drive growth and
resistance (Gordan et al, 2008; Paez-Ribes et al, 2009; Brannon et al,
2010; Huang et al, 2010; Finke et al, 2011).
POTENTIAL MOLECULAR PREDICTIVE BIOMARKERS
TO CURRENT SYSTEMIC AGENTS
High-dose (HD) interleukin (IL)-2
Histological factors The HD IL-2 remains an important
component of decision making due to B7% of selected patients
enjoying durable remissions. In addition to the benefit in a small
minority of patients, the toxicities, especially B3 potential
toxic death rate suggest the need for predictive biomarkers. In a
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www.bjcancer.comretrospective analysis of 163 patients receiving HD IL-2, those
with non-CC-RCC or with CC-RCC with papillary, no alveolar
and/or 450% granular features appeared to respond poorly
(Upton et al, 2005).
Tumour tissue factors Although historical data suggested that
high tumour CAIX (expression in 485% tumour cells) may be
predictive for benefit from HD IL-2, the phase II SELECT trial
(n¼120) failed to demonstrate the predictive value of tumour
CAIX expression on overall response rate (Leibovich et al, 2003;
Atkins et al, 2005; McDermott et al, 2010). Specifically, the trial did
not demonstrate a doubling of response rate in the clinically
defined good risk group compared with the poor risk group.
Conversely, the clinical high-risk SANI (Survival after Nephrect-
omy and Immunotherapy) group demonstrated a dismal PFS,
suggesting that clinicopathological features may help select
patients unlikely to benefit from HD IL-2. The SANI score is
composed of lymph node status, constitutional symptoms, location
of metastases (site other than lung or bone or multiple sites
of metastases), sarcomatoid histology and TSH level (Leibovich
et al, 2003).
Table 1 Current algorithm for management of advanced RCC
Setting Patients Primary therapy Other options
First line Good or intermediate risk
a Sunitinib
BevacizumabþIFN
Pazopanib
HD IL-2
Sorafenib
Observation
Poor risk
a Temsirolimus Sunitinib
Pazopanib
Second line Post cytokine Sorafenib
Pazopanib
Axitinib
Sunitinib
Bevacizumab
Temsirolimus
Post VEGF inhibitor Everolimus
Axitinib
Other VEGF inhibitors
Temsirolimus
Post mTOR inhibitor Axitinib Other VEGF inhibitors
Third line Post TKI-TKI Everolimus Temsirolimus
Post mTOR-TKI or
Post TKI-mTOR
Different TKI Rechallenge TKI
Abbreviations: HD¼high dose; IFN¼interferon; IL¼interleukin; mTOR¼
mammalian target of rapamycin; TKI¼tyrosine kinase inhibitor; VEGF¼vascular
endothelial growth factor.
aBased on anaemia, hypercalcaemia, KPSo80%, time from
diagnosis to treatment o1 year and high LDH (Motzer et al, 2002); prognostic
factors identified in patients receiving first-line VEGF-targeting therapy were: anaemia,
hypercalcaemia, KPS o80%, time from diagnosis to treatment o1 year, neutrophilia
and thrombocytosis (Heng et al, 2009).
PI3K
Akt
mTOR
VHL
alteration
PTEN
S6K
HIF
VEGF
VEGFR2
sVEGFR2
MDSC
IL-8
PDGF
Ang
FGF
ephrin
PlGF
CEC
MAPK
ERK
Met
IGFR
Integrins
Temsirolimus
everolimus
Bev
Pazopanib
sunitinib
axitinib
sorafenib
CAIX
myc
Wnt
DNA-repair
pathways
Epigenetic
pathways
Figure 1 Candidate molecular biomarkers for the therapy of advanced RCC with VEGF or mTOR inhibitors. Abbreviations: Bev¼bevacizumab; CEC¼circulating
endothelial cells; FGF¼fibroblast growth factor; HIF¼hypoxia-inducible factor; IGFR¼insulin-like growth factor receptor; IL-8¼interleukin-8; MDSC¼myeloid-
derived suppressor cells; PDGF¼platelet derived growth factor; PlGF¼placental growth factor; VEGFR2¼VEGF receptor 2; VHL¼Von Hippel Lindau.
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Histological factors In a retrospective study, a higher clear-cell
component was independently associated with better outcomes
from VEGF receptor tyrosine kinase inhibitors (Choueiri et al,
2010). It has also been observed in phase II trials that non-CC-RCC
demonstrates substantially lower response rates and PFS with
VEGF inhibitors, compared with CC-RCC (Choueiri et al, 2008a;
Lee et al, 2012b). Among patients with sarcomatoid RCC, partial
responses with VEGF inhibitors were limited to patients who had
underlying CC histology and o20% sarcomatoid elements
(Golshayan et al, 2009).
Tumour tissue factors In a retrospective study of 123 patients
receiving sunitinib, sorafenib, axitinib or bevacizumab, VHL
inactivation was not associated with overall response, PFS or
overall survival (OS). However, those with loss-of-function muta-
tions (frameshift, nonsense, splice and in-frame deletions/inser-
tions) had a significantly higher response rate compared with those
with wild-type VHL, even after adjustment for several clinical
variables (52% vs 31%, P¼0.04) (Choueiri et al, 2008b). Another
study (n¼118) identified heterogeneity in tumour responsiveness
to sunitinib or sorafenib according to CAIX status (Choueiri et al,
2010). Although CAIX expression had no prognostic value, it
appeared to be predictive for response to sorafenib. When
examining high vs low tumour CAIX expression by IHC, the mean
tumour regresion was  17% vs  25% for sunitinib and  13% vs
þ9% for sorafenib therapy (P¼0.05). Nevertheless, a follow-up
study looking at patients treated on the TARGET trial (133
evaluable with baseline tumour tissue out of 903 enrolled) did not
corroborate CAIX (by IHC) to be either predictive or prognostic in
patients receiving sorafenib (Qu et al, 2012). In another study of 43
patients, frozen tumour HIF levels (by western blot) were
associated with sunitinib sensitivity (Patel et al, 2008). Patients
with high tumour HIF1a or HIF2a were significantly more likely to
respond to sunitinib, relative to tumours containing low levels. A
total of 92% (12 out of 13) tumours with high HIF2a vs 13% (2 of 15)
with no detectable HIF2a responded. Supportive evidence was
provided by RCC cells lines where 5 out of 10 lines showing high
HIF1a and 2a by western blot were sensitive to sunitinib. Sunitinib
decreased pS6K and HIF2a rapidly in vitro, but did not inhibit the
phosphorylation of activated receptor tyrosine kinases, AKT or
ERK. Moreover, downregulation of HIF by insertion of VHL into
sensitive cells conferred resistance.
Plasma studies Plasma proteins were analysed to identify
biomarkers in a subset of patients enrolled in the Treatment
Approaches in Renal Cancer Global Evaluation Trial that evaluated
sorafenib vs placebo (Escudier et al, 2009; Pena et al, 2010).
Baseline biomarker data were available for VEGF (n¼712), soluble
(s)-VEGFR-2 (n¼713), CAIX (n¼128), tissue inhibitor of
metalloproteinase (TIMP)-1 (n¼123), Ras p21 (n¼125) and
VHL mutational status (n¼134). Higher performance status
correlated with elevated baseline VEGF and VHL mutations,
whereas higher risk grouping correlated with elevated VEGF, CAIX
and TIMP-1. Analyses identified baseline VEGF, CAIX, TIMP-1
and Ras p21 as prognostic for survival, but not predictive for
benefit. Nevertheless, patients with baseline VEGF concentrations
in the highest quartile gained the most PFS benefit from sorafenib.
The TIMP-1 remained prognostic for survival in a multivariable
analysis model that included performance status, risk group and
other biomarkers. In the placebo cohort, TIMP-1 and Ras p21
levels increased at 12 weeks. In the sorafenib cohort, VEGF levels
increased, whereas sVEGFR-2 and TIMP-1 levels decreased.
However, baseline sVEGFR-2 and changes in VEGF or sVEGFR-2
with treatment were not predictive of response.
The concentrations of 52 plasma cytokine and angiogenic
factors (CAFs) were measured in patients receiving sorafenib alone
or with interferon (IFN) (n¼69) to identify an association with
outcomes (Zurita et al, 2012). A CAF signature (osteopontin,
VEGF, CAIX, collagen IV, VEGF receptor-2 and tumour necrosis
factor-related apoptosis-inducing ligand (TRAIL) correlated with
PFS benefit from the combination, whereas another signature
predicted benefit from sorafenib alone. Levels greater than the
cut-off were associated with shorter PFS in the combination arm
for all markers except TRAIL, which showed the opposite effect.
Although changes in angiogenic factors were frequently attenuated
by the sorafenibþIFN combination, most immunomodulatory
mediators increased.
Following one cycle of sunitinib in a nonrandomised phase II
trial enrolling cytokine-pretreated patients (n¼63), VEGF and
placental growth factor plasma levels commonly increased 43-fold
relative to baseline (Deprimo et al, 2007). The sVEGFR-2 and
sVEGFR-3 levels decreased and tended to return to near baseline
after 2 weeks of treatment. Overall, significantly larger changes in
VEGF, sVEGFR-2 and sVEGFR-3 levels were observed in respond-
ing patients. Furthermore, baseline sVEGFR-3 and VEGF-C below
the median were associated with better outcomes in a phase II trial
(n¼61) that evaluated sunitinib following prior bevacizumab
exposure (Rini et al, 2008). One group of investigators studied 85
patients that received sunitinib and identified baseline serum VEGF
and neutrophil gelatinase-associated lipocalin as prognostic,
independent of clinicopathological factors (Porta et al, 2010). In a
phase II study (n¼225) in metastatic RCC receiving pazopanib,
response correlated with a decrease in plasma sVEGFR2
(P¼0.00002) but not with tumour VHL status or other soluble
markers (sVEGFR1, VEGF and CEC) (Hutson et al, 2008, 2010).
Host genetic factors Host genetics, which governs drug metabo-
lism and the constitution of the microenvironment in which the
tumour resides, can be anticipated to have an impact on clinical
outcomes. Germline variants in angiogenesis and exposure-related
genes were demonstrated to potentially predict response to
pazopanib in a retrospective analysis of 397 evaluable patients
from a phase III trial (Xu et al, 2011). Three polymorphisms in
IL-8 and HIF1a and five polymorphisms in HIF1a, NR1I2 and
VEGF-A were associated with outcomes (Table 2). Compared with
the wild-type AA genotype, the IL-8 2767TT genotype exhibited
inferior median PFS (48 vs 27 weeks, P¼0.009). The HIF1A
1790AG genotype was associated with inferior outcomes compared
with the wild-type GG genotype (median PFS, 20 vs 44 weeks;
P¼0.03). Reductions in RR were detected for the NR1I2-25385TT
genotype, compared with the wild-type CC genotype (37% vs 50%,
P¼0.03), and for the VEGFA-1498CC genotype compared with the
TT genotypes (33% vs 51%). In another study of 63 patients treated
with sunitinib, VEGF single-nucleotide polymorphism (SNP)-634
was associated with HTN and a combination of VEGF SNP 936
and VEGFR2 SNP 889 genotypes was associated with survival
(Kim et al, 2012). Interestingly, in the setting of advanced breast
cancer receiving bevacizumab, certain VEGF genotypes were
associated with hypertension and appeared to derive a preferential
benefit (Schneider et al, 2008). In another study, IL-4 promoter
variants carried prognostic value in metastatic RCC, possibly
through regulation of immune surveillance (Kleinrath et al, 2007).
Similarly, SNPs in VEGF and MDM2 appeared prognostic (Hirata
et al, 2007; Kawai et al, 2007).
Mammalian target of rapamycin inhibitors
Histological factors Temsirolimus is considered by some to be
the defacto conventional therapy for non-CC-RCC based on the
substantial proportion of these patients enrolled in the phase III
temsirolimus trial. Moreover, non-CC patients also appeared
to have an unanticipated benefit relative to the CC-RCC patients
in this trial (Hudes et al, 2007).
Tumour tissue factors Tumour pS6 and pAkt expression may be
promising predictive biomarkers for response to temsirolimus
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from 20 patients who had received temsirolimus underwent IHC
for mediators or downstream molecules of the mTOR pathway
(phosphorylated (p)-S6, pAkt and PTEN), CAIX and VHL
mutational analysis. There was a positive association of pS6
expression (P¼0.02) and a trend toward positive expression of
pAkt (P¼0.07) with response to temsirolimus. No patient without
high expression of either pS6 or pAkt demonstrated tumour
regression. There was no correlation of CAIX, PTEN or VHL status
with regressions. Furthermore, analysis of tumour from patients
treated with temsirolimus in the randomised phase III trial found
no correlation between PTEN or HIF1a expression and outcomes
(Figlin et al, 2009). In another study, the mTOR pathway was
found to be activated in metastases with correlation between
different components of this signalling cascade, but without PTEN
deletion (Abou Youssif et al, 2011). Only cytoplasmic p-mTOR was
independently prognostic and demonstrated concordance between
primary and metastasis.
Plasma-based factors Baseline serum LDH may be a potential
pretreatment predictive biomarker for the benefits conferred by
mTOR inhibitors in patients with poor-risk RCC (Armstrong et al,
2012). In this retrospective analysis of the phase III trial, among 140
patients with elevated LDH, survival was significantly improved with
temsirolimus compared with IFN (6.9 vs 4.2 months, Po0.002).
Conversely, among 264 patients with normal LDH, survival was not
improved with temsirolimus compared with IFN (11.7 vs 10.4
months, P¼0.514). Adjusting for known prognostic factors, the HR
for death was 2.01 for patients with LDH 41 upper limit of normal
(ULN) vs p1U L N( Po0.0001). Intriguingly, a decline in LDH with
therapy was also prognostic for OS (Po0.0001).
EARLY TOXICITIES AS PHARMACODYNAMIC
BIOMARKERS FOR ANTI-TUMOUR ACTIVITY
Vascular endothelial growth factor inhibitors
HTN appears to be a pharmacodynamic marker correlating with
outcomes with sunitinib (Rini et al, 2011a). This retrospective
analysis included pooled efficacy (n¼544) and safety (n¼4917)
data from four studies evaluating sunitinib. Blood pressure (BP)
was measured on days 1 and 28 of each 6-week cycle. Efficacy and
toxicities were compared between patients with and without HTN
(maximum systolic BP (SBP)X140mmHg or diastolic BP
(DBP)X90mmHg). Patients with systolic HTN had better out-
comes than those without HTN (RR: 54.8% vs 8.7%; median PFS:
12.5 vs 2.5 months and OS: 30.9 vs 7.2 months). Similarly, HTN
defined by DBP was also associated with improved outcomes.
Rates of adverse events were similar with and without HTN defined
by mean SBP, although hypertensive patients experienced more
renal adverse events. Similarly, a retrospective analysis of a phase
III trial (n¼716) demonstrated that patients receiving bevacizu-
mab who developed grade X2 HTN had improved outcomes
(Harzstark et al, 2010). On multivariable analysis, HTN at 2
months was an independent predictor of OS (HR 0.62, P¼0.046).
Moreover, in an 8-week landmark analysis of 230 patients, the
efficacy of axitinib was associated with DBP X90mmHg (Rini
et al, 2011b). Prospective randomised phase II (NCT 00835978)
comparison of the standard dose vs dose titration and escalation of
axitinib to attain hypertension and enhance outcomes is ongoing
(Table 3). One retrospective study of 770 patients from prospective
trials suggested that hand-foot syndrome (HFS) may serve as a
predictive biomarker of sunitinib efficacy. The 179 patients (23%)
who developed any-grade HFS had significantly better response
rate (55.6% vs 32.7%), PFS (14.3 vs 8.3 months), and OS (38.3 vs
18.9 months) compared with those who did not develop HFS
(Po0.0001). In a multivariate analysis, sunitinib-associated HFS
remained a significant independent predictor of OS even by time-
dependent analysis (Michaelson et al, 2011).
The mTOR inhibitors
One retrospective study reviewed 44 patients metastatic RCC
treated with temsirolimus or everolimus to investigate the
association of drug-induced interstitial pneumonitis and outcomes
(Dabydeen et al, 2011). Stable disease was achieved in 12 out of 14
patients (86%) who developed pneumonitis compared with 13 out
of 30 (43%) without pneumonitis. Progressive disease (PD) was
present in 1 out of 14 patients (7%) who developed pneumonitis
compared with 16 out of 30 (53%) without pneumonitis. The mean
Table 2 Reported potentially predictive molecular biomarkers in advanced RCC
Author
(reference)
Number of
patients Tissue Biomarker
Therapeutic
agent Predictive finding
Choueiri et al, 2008b 123 Tumour VHL mutations Sorafenib or sunitinib VHL loss of functions had higher RR than wild-type VHL
Choueiri et al, 2010 118 Tumour CAIX Sorafenib or sunitinib CAIX amplification associated with response to sorafenib but not sunitinib
Qu et al, 2012 133 Tumour CAIX Sorafenib CAIX was neither prognostic nor predictive
Patel et al, 2008 43 Tumour HIF Sunitinib High HIF1a or HIF2a tumours more likely to respond
Xu et al, 2011 397 Host Angiogenesis and
exposure-related genes
Pazopanib Polymorphisms in IL-8, HIF1A, NR1I2 and VEGFA were associated with
outcomes
Kim et al, 2012 63 Host VEGF polymorphisms Sunitinib Combination of VEGF SNP 936 and VEGFR2 SNP 889 was associated with
survival
Escudier et al, 2009;
Pena et al,2 0 1 0
713 Plasma VEGF pathway Sorafenib VEGF, CAIX, TIMP-1, Ras and p21 prognostic for survival, but not predictive for
benefit
Zurita et al, 2012 69 Plasma CAFs Sorafenib±IFN CAF signature (osteopontin, VEGF, CAIX, collagen IV, VEGF receptor-2 and
TRAIL) correlated with better PFS from the combination, and another
signature predicted for benefit from sorafenib alone
Deprimo et al, 2007 55 Plasma VEGF and PLGF pathways Sunitinib Larger increases in VEGF, sVEGFR-2, and decreases in sVEGFR-3 in responding
patients
Rini et al, 2008 61 Plasma VEGF pathway sunitinib Baseline sVEGFR-3 and VEGF-C below median were associated with better
outcomes
Hutson et al, 2008 78 Plasma, Tumour
tissue
VEGF pathway, CECs and
tumour VHL
Pazopanib Tumour response correlated with decrease in sVEGFR2, but not with VHL
status or other markers
Cho et al, 2007 20 Tumour mTOR pathway Temsirolimus High pS6K significantly associated and high pAkt trending to be associated with
response; no correlation of CAIX, PTEN or VHL status with regression
Figlin et al, 2009 416 Tumour PTEN and HIF-1a Temsirolimus No association with response
Armstrong et al, 2012 404 Plasma LDH Temsirolimus Survival was extended with baseline LDH 4ULN vs pULN; also, a decline in
LDH with therapy was prognostic
Abbreviations: CAF¼cytokine and angiogenic factor; CAIX¼carbonic anhydrase IX; CEC¼circulating endothelial cell; HIF¼hypoxia-inducible factor; IFN¼interferon;
IL¼interleukin; LDH¼lactate dehydrogenase; PFS¼progression-free survival; PLGF¼placental growth factor; RR¼response rate; SNP¼single-nucleotide polymorphism;
sVEGFR2¼soluble VEGF receptor 2; TIMP¼tissue inhibitor of metalloproteinase; TRAIL¼tumour necrosis factor-related apoptosis-inducing ligand; ULN¼upper limit of
normal; VHL¼Von Hippel Lindau; VEGF¼vascular endothelial growth factor.
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group and þ4.13% in the non-pneumonitis group (P¼0.005). In a
retrospective analysis of the Global Advanced Renal Cell Carcinoma
phase III trial (416 evaluable patients), hypercholesterolaemia with
temsirolimus was associated with prolonged survival (HR 0.77 per
mmoll
 1, Po0.0001), whereas the effect on triglycerides or glucose
was not associated with survival (Lee et al, 2012a). However,
biomarkers reliant on early changes are inherently less useful than
biomarkers present at baseline (because baseline markers do not
warrant the initiation of therapy, sometimes associated with expense
and toxicities, before measurement).
FUNCTIONAL IMAGING
The mTOR inhibitors decrease glucose uptake and may be
expected to downregulate fluoro-deoxy-glucose positron emission
tomography (FDG-PET) uptake. However, one study suggested
that FDG-PET uptake correlated with pAkt expression but did not
predict mTOR inhibitor activity (Ma et al, 2009). Unfortunately, a
phase II trial evaluating early FDG-PET changes to predict benefit
from second-line everolimus could detect only a modest associa-
tion with tumour regressions (Chen et al, 2011). In patients
receiving sunitinib, baseline high FDG PET uptake and increased
number of positive lesions appeared to yield prognostic informa-
tion. Additionally, PET-computerised tomography progression at
16 weeks was associated with poor survival (Katani et al, 2011).
Changes in vascular perfusion as imaged by dynamic contrast
enhanced (DCE)-magnetic resonance imaging parameters after 4
weeks of sorafenib were not predictive for outcomes and
were characterised by high variability and low magnitude of
effect (Hahn et al, 2008). Another small study suggested that
DCE-ultrasound changes may facilitate the prediction of efficacy of
sunitinib (Lassau et al, 2010).
FUTURE DIRECTIONS AND CHALLENGES WHEN
DEVELOPING BIOMARKERS
Hypothetically, agents should probably be developed in molecu-
larly enriched subsets likely to benefit across different tumours
rather than in trials dedicated to morphological tumour subtypes.
The therapeutic landscape for metastatic CC-RCC has witnessed
the addition of a large number of VEGF and mTOR inhibitors.
However, the critical determinants of response to each of these
agents, which have slightly differing molecular targets and
potencies, are unclear. Paradoxically, the rapid pace of expansion
of the therapeutic armamentarium and commercial availability of
multiple agents has hampered the development of predictive
biomarkers. Moreover, the discovery studies performed heretofore
are limited by small sample sizes and heterogeneous populations.
Hence, large multicenter data sets are necessary to discover
potential biomarkers. Notably, a 16-gene panel remained sig-
nificantly associated with recurrence-free interval independent of
clinical and pathological factors (necrosis, grade, stage, tumour
size and lymph node involvement) in a study of 931 patients with
localised RCC following nephrectomy (Rini et al, 2010). Lower
recurrence was observed for angiogenesis (EMCN and NOS3) and
immune-related (including CCL5 and CXCL9) genes. Thus, with
further validation in the setting of randomised phase III trials,
molecular biomarkers may assist in selection of high-risk patients
likely to benefit from adjuvant therapy. Thereafter, in addition to
carefully validating selected candidate genomic and proteomic
biomarkers, metabolomic and micro-RNA profiling also need
study. In conjunction with these efforts, standardisation of tissue
sample acquisition, storage and analysis are imperative to enhance
reproducibility and enable generalisability (Di Napoli and
Signoretti, 2009). This problem is illustrated by the challenges
still being encountered after years and even decades of clinical use
of biomarkers in other settings, for example, IHC for Her2 and
oestrogen receptor to guide breast cancer therapy.
A combination of clinicopathological and molecular factors may
optimise patient selection for specific agents. More specifically, the
molecular profile should provide a clinically meaningful increment
in predictive performance over conventional clinical factors. The
development of such predictive models may be complicated by
the differing utility of specific molecular biomarkers based on the
clinical risk group and specific agent being considered (Vickers
et al, 2008). Despite the challenges and complexities, the predictive
model should be characterised by optimal performance and be
user-friendly to enable its employment at the bedside. Given the
moderate increment in median PFS with the available VEGF and
mTOR inhibitors, the vast majority of patients (70–80%) benefit to
some extent, whereas a minority (20–30%) of patients have
primary refractory disease. Thus, it may be important to prioritise
biomarker development to initially identify baseline biomarkers
for resistance in order to avoid subjecting those with primary
refractory disease to futile and potentially toxic therapy. Multiple
trials are attempting to combine bevacizumab with mTOR
inhibitors, which may warrant the incorporation of biomarkers
to identify subsets that preferentially benefit. The utility
of biomarkers may be even more important in the setting of
combinations, which may yield greater toxicities than single
agents. Incorporation of biomarkers in the early development of
novel agents in clinical trials is important to guide late-phase
development, for example, tumour B7-H1 expression may be
associated with response to PD-1-inhibiting agents to bolster the
anti-tumour immune response, as suggested by a phase I trial
(Brahmer et al, 2010).
Table 3 Ongoing trials developing predictive biomarkers in RCC
Trial Agent
Phase
of trial
Target
accrual Design of trial
Tissue being
analysed Biomarker
NCT 01297244 Tivozanib II 100 Open-label non-randomised Tumour and
plasma
Tumour tissue: CD68, HIF1/HIF2, VEGF A, VEGF-B, VEGF-
C, VEGF-D, HGF, CAIX, PLGF and transcriptional profiles
Plasma: VEGF-A, VEGF-B, VEGF-C, VEGF-D, HGF, and
PLGF levels, protein expression, metabolite patterns and
PK studies
NCT 00835978 Axitinib II 200 Double-blinded randomised with
or without dose titration
Plasma PK
studies
HTN
NCT00827359 Everolimus II NA Open label non-randomised Tumour NA
NCT00831480 Everolimus II 27 Open label non-randomised with
brief neoadjuvant therapy
preceding CN
Tumour,
plasma
Tumour tissue at baseline and post-therapy: proteomic and
genomic studies, miRNA profiling, Plasma PK studies
Abbreviations: CAIX¼carbonic anhydrase IX; CN¼cytoreductive nephrectomy; HGF¼hepatocyte growth factor; HIF¼hypoxia-inducible factor; HTN¼hypertension;
miRNA¼micro RNA; NA¼not applicable; PK¼pharmacokinetic; PLGF¼placental growth factor; VEGF¼vascular endothelial growth factor.
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intratumor heterogeneity, which is underestimated by single
tumour-biopsy samples. Molecular heterogeneity may promote
adaptation and hinder personalised medicine as demonstrated in a
recent study (Gerlinger et al, 2012). This study examined this issue
by performing IHC, exome sequencing, chromosome aberration
analysis and ploidy profiling on multiple spatially separated
samples obtained from primary renal carcinomas and associated
metastatic sites. Analysis revealed that 63–69% of all somatic
mutations (including mTOR) were not detectable across every
tumour region. Interestingly, gene-expression signatures of good
and poor prognosis were detected in separate regions of the same
tumour.
The neoadjuvant paradigm may assist in expediting the
development of predictive biomarkers. In one trial of patients
receiving bevacizumab plus erlotinib (n¼23) or bevacizumab
alone (n¼27) for 8 weeks, frozen nephrectomy tumour specimens
were subjected to correlative studies and compared with untreated
controls (Jonasch et al, 2009). High tumour total AMPK (which
regulates the PI3K pathway) and low PI3K pathway expression
(low pAkt, low pS6K, high PTEN) correlated with longer survival,
which may be a candidate pathway that interacts with the VEGF
pathway and is a potential resistance mechanism. However, it is
unclear if this tumour tissue profile is present at baseline or is
induced by bevacizumab. An ongoing phase II trial
(NCT00831480) is evaluating frontline everolimus administered
before CN for metastatic RCC (Table 3, Figure 2). Patients undergo
a baseline biopsy of the renal tumour followed by 3–5 weeks of
everolimus before CN. Following surgery, everolimus is resumed
and continued until progression or intolerable toxicity. Modula-
tion of the mTOR signalling pathway and downstream prolifera-
tion, apoptosis and angiogenesis in the nephrectomy tumour
specimen will be correlated with time to progression. Potentially,
baseline markers as well as biological alterations in the tumour
with brief therapy during a window of opportunity may predict
long-term outcomes. However, this paradigm will only be
applicable to patients presenting with metastatic disease who have
not undergone prior nephrectomy. Brief neoadjuvant therapy
evaluating highly tolerable novel agents before excision of localised
high-risk RCC may also be worthy of utilisation to obtain signals of
biological activity and develop predictive biomarkers. Moreover,
functional imaging of tumour proliferation, metabolic pathways
and vascular perfusion requires a commitment to prospective
evaluation and validation.
CONCLUSIONS
Renal cell carcinoma is not one disease but comprises a spectrum
of subtypes based on different molecular drivers and host genetic
backgrounds. Predictive biomarkers are in their infancy of
development, but should be a priority in early preclinical and
clinical development in order to guide rational tailored develop-
ment of emerging agents. Multiple early prospective efforts to
study biomarkers are ongoing (Table 3). The current economic
climate demands a more focused development of new agents in
populations likely to enjoy larger increments in outcomes than
currently observed in unselected populations. Rational delivery of
therapeutic agents is intimately coupled with molecular biomar-
kers in the contexts of breast cancer (Her2 predictive for benefit
from Her2 inhibitors, Recurrence Score (Oncotype-DX, Genomic
Health, Redwood City, CA, USA) predictive for benefit from
adjuvant chemotherapy in oestrogen receptor-amplified breast
cancer), colorectal cancer (K-ras wild type predictive for benefit
from EGFR-inhibiting monoclonal antibodies), melanomas (V600E
Raf kinase mutation predictive for benefit from Raf kinase
inhibitors) and non-small cell lung cancer (EML4-ALK transloca-
tions or EGFR mutations to predict benefit from ALK and EGFR
inhibitors, respectively). Hopefully, the rational selection of agents
for the therapy of RCC will also take a step in this direction.
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